“triple-negative-breast-cancer” Archives

in
Entry Author Date Location
Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout 09/14/20 San Francisco
Now Closer to Clinical Trials, Codiak BioSciences Refiles IPO Plans 09/10/20 Boston
AstraZeneca to Pay $1B to Team Up With Daiichi Sankyo Again in Cancer 07/27/20 Europe
Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs 05/08/20 National
Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod 04/22/20 New York
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More 02/14/20 National
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More 08/02/19 National
Merck Data Are Another Step for Immunotherapy in Breast Cancer 07/29/19 New York
Immunotherapy Is Now Here For Breast Cancer. What Are Its Prospects? 05/29/19 National
AACR 2019 Roundup: Notes from a Weekend of Early Stage Cancer Results 04/03/19 National
Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More 03/15/19 National
Evestra Snags DoD Grant For Experimental Breast Cancer Drug Research 02/22/18 Texas
Texas Cancer Center Seeks to Speed Discovery with Applied Research 12/03/14 Texas
East Coast Biotech Roundup: Dicerna, J&J, Neurophage, & More 01/31/14 Boston
MD Anderson Expands “Moon Shots” Immunotherapy Partnership to J&J 01/21/14 Texas
Verastem, Rooted at MIT, Raises $32 Million and Adds ATV and Astellas to Slate of Investors 07/14/11 Boston
Page 1 of 1